Fig. 1



AE 19/24/33 2012 MC38 Tumors Anti-VEGF/Ang-2 + CD40 in 20g female mice
Control
Anti-VEGF
Anti-Ang-2
Anti-VEGF/Ang-2
Anti-CD40 (IgG1)
Anti-VEGF + Anti-CD40 (IgG1)
Anti-Ang-2 + Anti-CD40 (IgG1)
Anti-VEGF/Ang-2 + Anti-CD40
Percent survival
Time (days)
0
20
40
60
80
100
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150

Fig. 2A



Tumor Volume Development
mouse IgG
CD40 Ab (FGK45 mouse IgG2a)
Tumor Volume [mm³] (Mean) +/- SEM
2500
2000
1500
1000
500
0
7
10
14
17
21
Day after tumor cell inoculation

Fig. 2B



Tumor Volume Development
Tumor volume (mm³) Mean +/- SEM
1000
900
800
700
600
500
400
300
200
100
0
5
10
15
20
Day after tumor cell inoculation
mouse IgG
Ang2-VEGF (murine B20/LC06 CrossMab)

Fig. 2C




Tumor Volume Development
mouse IgG
Ang2-VEGF (murine B20/LC06 CrossMab) + CD40 Ab (FGK45 IgG2a)
Tumor Volume [mm³] Mean +/- SEM
2500
2000
1500
1000
500
0
7
9
11
14
16
18
21
23
25
28
30
32
Day after tumor cell inoculation

Fig. 3


Vehicle
A2V
CD40
A2V + CD40
Tumor volume [mm3] +/- IQR
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
12
14
16
18
20
22
24
26
Study Day